title: [Chemotherapy and immunomodulating treatment of patients with multiple myeloma].
abstract: Prospective studies were carried out on the effectiveness of various treatment methods in 208 patients with plasmocytic myeloma. In 102 patients induction therapy was based exclusively on melphalan, in 106 cases polychemotherapy was used including vincristine, melphalan, carmustine, cyclophosphamide and prednisone. The differences in the per cent of patients with good response to treatment and in the survival time after treatment beginning were statistically not significant between these groups which suggests that polychemotherapy begun from the diagnosis of the disease is justified in patients with large mass of the neoplasm and poor prognostic factors. In 45 patients chemotherapy was supported by administration of immunomodulatory agents, including calf thymus extract in 25 cases, levamisole in 18 and interferon in 2. It was observed that maintenance of remission with chemotherapy and with immunomodulatory agents calf thymus extract or levamisole prolonged the survival of the patients. In cases of leucopenia the use of calf thymus extract facilitated chemotherapy by stimulation of myelopoiesis.
authors.affiliation: Kliniki Hematologicznej Instytutu Hematologii, Warszawie.
authors.forename: M
authors.initials: M
authors.lastname: Kraj
authors.forename: A
authors.initials: A
authors.lastname: Dmoszyńska
authors.forename: S
authors.initials: S
authors.lastname: Maj
authors.forename: J
authors.initials: J
authors.lastname: Kowalewski
authors.forename: J
authors.initials: J
authors.lastname: Rostkowska
authors.forename: R
authors.initials: R
authors.lastname: Pogłód
authors.forename: B
authors.initials: B
authors.lastname: Sokołowska
authors.forename: E
authors.initials: E
authors.lastname: Mendek-Czajkowska
authors.forename: M
authors.initials: M
authors.lastname: Kurowska
authors.forename: U
authors.initials: U
authors.lastname: Sokołowska
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002330:Carmustine / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage*; D007978:Levamisole / Q000008:administration & dosage*; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D009101:Multiple Myeloma / Q000401:mortality / Q000628:therapy*; D011241:Prednisone / Q000008:administration & dosage; D012074:Remission Induction; D013949:Thymus Extracts / Q000008:administration & dosage*; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D016898:Interferon-alpha; C019108:TFX; D013949:Thymus Extracts; D007978:Levamisole; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D008558:Melphalan; D002330:Carmustine; D011241:Prednisone
vernacular_title: Chemioterapia i leczenie immunomodulacyjne u chorych na szpiczaka plazmocytowego.